Status:
UNKNOWN
Lithium Therapeutic Drug Monitoring; Once Daily Vs Twice Daily Dosing and the Impact of Kidney Function
Lead Sponsor:
Mount Sinai Hospital, Canada
Conditions:
Bipolar Disorder
Major Depressive Disorder
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Lithium is a mainstay in the treatment of bipolar disorder, and a frequently used adjunctive therapy for major depressive disorder. It is accepted practice to monitor lithium serum levels to monitor f...
Detailed Description
Bipolar disorder is a chronic and recurring condition which causes functional impairment and increases lifetime suicide risk. Major depressive disorder likewise confers a high burden of illness on the...
Eligibility Criteria
Inclusion
- Adult patients admitted to the inpatient psychiatry unit at Mount Sinai Hospital treated with lithium therapy (i.e. taking lithium before admission, or initiated on lithium therapy during hospitalization)
Exclusion
- any patients who are currently pregnant
- patients taking lithium three times daily
- patients taking lithium with a specific dosing frequency for a documented clinical reason.
Key Trial Info
Start Date :
February 6 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2019
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT03811860
Start Date
February 6 2019
End Date
December 1 2019
Last Update
March 8 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G 1X5